Clinical Pharmacokinetics and Pharmacology of Trimetrexate
- 1 March 1994
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 26 (3) , 190-200
- https://doi.org/10.2165/00003088-199426030-00003
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Leucovorin Enhances Chtotoxicity of Trimetrexate/Fluorouracil, But Not Methotrexate/Fluorouracil, in CCRF-CEM CellsJNCI Journal of the National Cancer Institute, 1992
- A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: A Southwest Oncology Group trialGynecologic Oncology, 1992
- Trimetrexate in advanced renal cell carcinomaInvestigational New Drugs, 1992
- Trimetrexate-Leucovorin Dosage Evaluation Study for Treatmentof Pneumocystis carinii PneumoniaThe Journal of Infectious Diseases, 1990
- Phase I Trial of Trimetrexate Glucuronate on a Five-Day Bolus Schedule: Clinical Pharmacology and PharmacodynamicsJNCI Journal of the National Cancer Institute, 1989
- Trimetrexate: Predictors of Severe or Life-Threatening Toxic EffectsJNCI Journal of the National Cancer Institute, 1988
- Potent Effect of Trimetrexate, a Lipid-Soluble Antifolate, on Toxoplasma gondiiThe Journal of Infectious Diseases, 1987
- Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediaminesJournal of Medicinal Chemistry, 1983
- Unstable Methotrexate Resistance in Human Small-Cell Carcinoma Associated with Double Minute ChromosomesNew England Journal of Medicine, 1983
- Inhibition of mammalian dihydrofolate reductase by selected 2,4-diaminoquinazolines and related compoundsJournal of Medicinal Chemistry, 1974